ProQR Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $6,336 | $4,476 | $3,199 | $1,370 |
Gross Profit | 5,622 | 3,781 | 3,199 | 1,370 |
EBITDA | -3,060 | -7,638 | -8,253 | -8,198 |
EBIT | -3,775 | -8,333 | -8,962 | -8,858 |
Net Income | -2,705 | -7,703 | -5,342 | -5,710 |
Net Change In Cash | 6,336 | 4,476 | 3,199 | 1,370 |
Free Cash Flow | -6,425 | -15,957 | -8,356 | -7,847 |
Cash | 79,016 | 85,792 | 119,023 | 120,552 |
Basic Shares | 81,665 | 81,571 | 78,460 | 81,000 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $6,380 | $4,037 | $1,354 | $243 |
Gross Profit | 6,380 | 1,561 | 1,354 | -2,194 |
EBITDA | -31,693 | -59,384 | -55,376 | -49,465 |
EBIT | -34,155 | -61,859 | -57,797 | -51,659 |
Net Income | -27,542 | -64,891 | -61,680 | -46,614 |
Net Change In Cash | 6,380 | 4,037 | 1,354 | 243 |
Free Cash Flow | 17,460 | -69,216 | -26,496 | -47,984 |
Cash | 119,023 | 94,775 | 187,524 | 75,838 |
Basic Shares | 81,011 | 71,641 | 64,182 | 50,060 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.03 |
2024-03-31 | -$0.09 |
2023-12-31 | -$0.07 |
2023-09-30 | -$0.07 |
